ClinicalTrials.gg
RecruitingNCT07524322Updated Nov 2, 2026

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

A Phase 1 interventional study of RGT-490 in Breast Cancer, Ovarian Cancer and Endometrial Cancer, sponsored by Regor Pharmaceuticals Inc.. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Regor Pharmaceuticals Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 2, 2026Start date moved1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer.

Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.

02

Conditions studied

  • Breast Cancer
  • Ovarian Cancer
  • Endometrial Cancer
  • PIK3CA Mutation
  • HER2- Negative Breast Cancer
  • Advanced Breast Cancer
  • Unresectable Solid Tumor
  • Hormone Receptor Positive Tumor
  • Cervical Cancer
03

In context

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

This study's planned enrollment of 63 is below the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Regor Pharmaceuticals Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with or locally advanced, unresectable solid tumors that have progressed on or after at least one available therapy.
  • Presence of one or more documented activating PIK3CA mutation in tumor tissue and/or blood.
  • At least 1 or evaluable disease per v1.1.
  • An performance status of 0 or 1.
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus requiring anti-hyperglycemic medication.
  • Prior treatment with PI3Kα inhibitors
  • Symptomatic, untreated, or uncontrolled central nervous system .
  • Receipt of any local or systemic anticancer therapy or anticancer agent within a protocol-defined prior to study treatment.
  • Unresolved toxicities from prior anticancer therapy
  • History of a another within 2 years prior to screening (exception adequately treated cancers).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    Phase 1 Dose Escalation (Advanced Solid Tumors with PIK3CA mutation)

    RGT-490 given alone as monotherapy

    Drug: RGT-490

  • Experimental
    Phase 1b Dose Expansion (HR+/HER2- locally advanced or metastatic breast cancer)

    RGT-490 given alone as monotherapy

    Drug: RGT-490

Interventions

  • DrugRGT-490

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (DLTs)

    Number of subjects who experience at least 1 Dose Limiting Toxicity (DLT)

    Time frame: 4 weeks (1 cycle)

  2. Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) and AEs leading to dose modifications and dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)

    Time frame: Every cycle (4-week cycles) until study discontinuation, approximately 12 months

Secondary outcomes

  1. Characterize the Cmax (PK) of RGT-490 monotherapy in Dose Escalation

    Maximum observed plasma concentration (Cmax) of RGT-490

    Time frame: First 3 treatment cycles (each cycle is 28 days)

  2. Characterize the Tmax (PK) of RGT-490 monotherapy in Dose Escalation

    Maximum observed plasma concentration (Tmax) of RGT-490

    Time frame: First 3 treatment cycles (each cycle is 28 days)

  3. Characterize the AUC (PK) of RGT-490 monotherapy in Dose Escalation

    Calculated area under the plasma concentration curve (AUC) of RGT-490

    Time frame: First 3 treatment cycles (each cycle is 28 days)

  4. Measure PD effects of RGT-490 monotherapy in Dose Escalation and Phase 1b

    Change from baseline in ctDNA levels; Change from baseline in PD markers in paired biopsies

    Time frame: First 7 cycles (each cycle is 28 days) and at study discontinuation

  5. Changes in fasting blood glucose

    Measured by fasting blood glucose

    Time frame: Approximately every week in Cycle 1 and Cycle 2 (4-week cycle), every 2 weeks in Cycles 3-6 (4-week cycle), and every cycle through end of treatment (4-week cycles), approximately 24 months

  6. Changes in longitudinal glucose metabolism (All Phases)

    Measured by HbA1c

    Time frame: Approximately every cycle (4-week cycles) until study discontinuation, approximately 24 months

  7. Assess preliminary efficacy of RGT-490 monotherapy in dose escalation and Phase 1b

    Objective response rate (ORR) based on RECIST v1.1

    Time frame: Approximately every 8 weeks until progressive disease, approximately 12 months

  8. Evaluate additional measures of efficacy of RGT-490

    Duration of response (DoR) according to RECIST v1.1

    Time frame: Approximately every 8 weeks until progressive disease, approximately 36 months

  9. Evaluate additional measures of efficacy of RGT-490

    Progression free survival (PFS) according to RECIST v1.1

    Time frame: Approximately every 8 weeks until progressive disease, approximately 36 months

07

Study locations

6 of 6 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2028, 21 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 21 months is below that.

Counting every sponsor, half of 762 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 13, 2026
StartActual
Jul 21, 2026was Jun 2026
Primary completionEst.
Apr 2028
CompletionEst.
Oct 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • University of Pittsburgh Medical Center · Pittsburgh, United States
Nov 2, 2026
Start date
Jun 2026→Jul 21, 2026 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added
    Show site
    • University of Pittsburgh Medical Center · Pittsburgh, United States
    Start date Jun 2026→Jul 21, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07524322
Lead sponsor
Regor Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Jul 21, 2026
Primary completion
Apr 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Sarah Wheeler
Contact
Sarah.Wheeler@regor.com
857-331-3898
Regor Pharmaceuticals Central Office
Contact
RGT-490-101@regor.com
617-315-9070

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion